S. Siddiqui (Leicester, United Kingdom), M. Adner (Stockholm, Sweden)
Late Breaking Abstract - Cardio-selective beta1-blockers in asthma: a search of the World Health Organization Global Database of Individual Case Safety reports (VigiBase)
M. Bennett (Manchester, United Kingdom), C. Chang (Hamilton, New Zealand), M. Tatley (Dunedin, New Zealand), R. Savage (Dunedin, New Zealand), R. Hancox (Dunedin, New Zealand)
|   |
Oral corticosteroid prescription in asthma: Swiss situation
C. Schuoler (Baar, Switzerland), J. Leuppi (Liestal, Switzerland), T. Rothe (Chur, Switzerland), A. Jochmann (Basel, Switzerland), C. Clarenbach (Zürich, Switzerland), C. Steurer-Stey (Zürich, Switzerland), F. Charbonnier (Geneva, Switzerland), H. Duchna (Davos, Switzerland), P. Bridevaux (Sion, Switzerland), V. Chicherov (Rotkreuz, Switzerland), M. Korobeynikova (Rotkreuz, Switzerland), S. Wetzel (Rotkreuz, Switzerland), C. Leuenberger (Baar, Switzerland), G. Pendl (Baar, Switzerland)
| |
Icaritin inhibited ovalbumin-induced airway inflammation in murine model
D. Yao (Guilin, China), B. Xiao (Guilin, China), G. Zhou (Guilin, China), B. Mo (Guilin, China)
| |
Reslizumab: Effectiveness one month after first dose.
I. Lobato Astiarraga (Ávila, Spain), M. López Zubizarreta (Ávila, Spain), A. Andrés Porras (Ávila, Spain), J. Marcos Sierra (Ávila, Spain), J. Tenes Mayen (Ávila, Spain), R. Pajares Mediavilla (Ávila, Spain), J. Tapias Del Pozo (Ávila, Spain), J. Hernández Hernández (Ávila, Spain)
| |
Assessment of biological therapy in asthma-obesity phenotype
E. Makarova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation)
| |
Diagnosis and therapy of asthma bronchiale in top athletes
É. Seres (Budapest, Hungary), N. Sydo (Budapest, Hungary), G. Horvath (Budapest, Hungary), T. Kovats (Budapest, Hungary), O. Kiss (Budapest, Hungary), B. Merkely (Budapest, Hungary), V. Muller (Budapest, Hungary)
| |
Budesonide/formoterol efficacy in “obese” asthma.
N. Slepchenko (Vinnytsya, Ukraine), Y. Mostovoy (Vinnytsya, Ukraine), N. Tsymbaliuk (Vinnytsya, Ukraine), A. Sidorov (Vinnytsya, Ukraine), K. Dmytriiev (Vinnytsya, Ukraine)
| |
Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
R. Dobek (Warsaw, Poland), W. Barg (Wroclaw, Poland), G. Bochenek (Kraków, Poland), G. Brozek (Katowice, Poland), D. Brzostek (Warsaw, Poland), P. Dabrowiecki (Warsaw, Poland), A. Dabrowski (Warsaw, Poland), R. Gawlik (Katowice, Poland), A. Kucharczyk (Warsaw, Poland), I. Kuprys-Lipinska (Lodz, Poland), A. Mastalerz-Migas (Wroclaw, Poland), E. Zagrajek (Warsaw, Poland), M. Kowalski (Lodz, Poland)
| |
Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma
A. Silberbrandt (Copenhagen, Denmark), M. Mukherjee (Hamilton, Canada), M. Hvidtfeldt (Copenhagen, Denmark), L. Frøssing (Copenhagen, Denmark), P. Nair (Hamilton, Canada), C. Porsbjerg (Copenhagen, Denmark)
| |
ß2-adrenoceptor (ß2-AR) dysfunction in airway smooth muscle in severe asthma: possible role of inflammatory cytokines
J. Hakeem (Leicester, United Kingdom), L. Chachi (Leicester, United Kingdom), F. Alhadian (Leicester, United Kingdom), M. Biddle (Leicester, United Kingdom), O. Tliba (New York, United States of America), P. Bradding (Leicester, United Kingdom), Y. Amrani (Leicester, United Kingdom)
| |
Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece.
M. Kallieri (Athens, Greece), E. Zervas (Athens, Greece), K. Katsoulis (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), K. Samitas (Athens, Greece), A. Papaioannou (Athens, Greece), M. Kipourou (Thessaloniki, Greece), P. Lyberopoulos (Athens, Greece), E. Gaki (Trikala , Greece), S. Vittorakis (Chania, Greece), M. Markatos (Chania, Greece), K. Dimakou (Athens, Greece), S. Ampelioti (Athens, Greece), S. Koukidou (Athens, Greece), M. Makris (Athens, Greece), M. Ntakoula (Athens, Greece), M. Mitrova (Thessaloniki, Greece), S. Papiris (Athens, Greece), N. Tzanakis (Crete, Greece), D. Papakosta (Thessaloniki, Greece), P. Bakakos (Athens, Greece), S. Loukides (Athens, Greece)
| |
High intensity interval training control inflammation in a lung allergic model.
P. da Rocha Trindade (Sao Paulo, Brazil), T. F.F. Castelo (Sao Paulo, Brazil), T. B.P. Castro (Sao Paulo, Brazil), R. M. Laia (Sao Paulo, Brazil), L. D. Mendonça (Sao Paulo, Brazil), J. C. Souza (Sao Paulo, Brazil), B. M. Saraiva-Romanholo (Sao Paulo, Brazil), C. M. Prado (Sao Paulo, Brazil), I. F.C.L. Tiberio (Sao Paulo, Brazil), C. Rosa Olivo (Sao Paulo, Brazil)
| |
Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle
L. Calzetta (Rome, Italy), B. Ritondo (Rome, Italy), I. Nikolaev (Basel, Switzerland), M. Cazzola (Rome, Italy), M. Matera (Naples, Italy), P. Rogliani (Rome, Italy)
| |
Broncho-alveolar lavage procedure extract compounds from surrounding tissue
E. Bäckström (Mölndal, Sweden), B. Fihn (Mölndal, Sweden), T. Erngren (Mölndal, Sweden), W. Lindberg (Mölndal, Sweden), L. Odqvist (Mölndal, Sweden), M. Fridén (Mölndal, Sweden), K. Grime (Mölndal, Sweden)
| |
The effects of PGD2 and DK-PGD2 on features of airway remodeling in human airway epithelial cells and guinea pig lung slices
S. Rahmawati (Groningen, Netherlands), V. Verschut (Groningen, Netherlands), M. Woest (Groningen, Netherlands), H. Kerstjens (Groningen, Netherlands), D. Sandham (Horsham, United Kingdom), R. Gosens (Groningen, Netherlands), L. Kistemaker (Groningen, Netherlands)
| |
Progesterone-induced blocking factor as a potential therapeutic target for elderly women with asthma
H. Shim (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), M. Pyo (Seoul, Republic of Korea), K. Moon (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), J. Choi (Seoul, Republic of Korea), H. Kwon (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea)
| |
GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects
S. Sahdeo (San Diego, United States of America), K. Taylor Meadows (San Diego, United States of America), S. Hoare (Owego, United States of America), T. Kenakin (Raleigh-Durham, United States of America), S. Murphy (San Diego, United States of America), T. Salter-Cid (San Diego, United States of America), H. Ortega (San Diego, United States of America), G. Opiteck (San Diego, United States of America), L. Salter-Cid (San Diego, United States of America), L. Carter (San Diego, United States of America)
| |
GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects
G. Opiteck (San Diego, United States of America), K. Taylor Meadows (San Diego, United States of America), E. Butz (Seattle, United States of America), S. Sugden (Montreal, Canada), R. Aranda (San Diego, United States of America), H. Ortega (San Diego, United States of America)
| |